Cyclopharm Limited (ASX:CYC)
Share Pricing & News Healthcare

AUD 1.4

-0.02 (1.409%)
(As on 2022-10-05 20:55:46 AEDT)
Previous Close Open Close*
1.42 1.4 1.4
Market Cap Dividend Yield (Annualized)
AUD 130.725M 0.61%

Day Range
1.395L 1.4 H
52 WEEK HIGH LOW
0.95L 2.14 H

Chart Price & Information

Last Trade 1.4
Change% -1.4085
52 W H/L 2.140/0.950
EBITDA -1.944M
NPAT After Abnormal Items -5.04M
Equity 43.068M
ROE% -12.03%
Total Liabilities 12.673M
Total Revenue 20.137M
Cash and Cash Equivalents 29.249M

Stock Information

Share price 1.4
Market Cap 130.725M
Price/Gross Cash Flow -65.92
Dividend Yield Excluding Special 0.61%
Ending Shares 93.375M
52-Week Range 2.140-0.950
Gross DPS (AUD) 0.01
Gross Dividend Yield (Annualized) 0.61%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.40
P/E ratio 0.000
Sector P/E --
EPS -5.63
EV/EBITDA --
Net Profit Margin (%) -29.27%
Gross Cash Flows Per Share -0.03
Net Gearing -57.44%
Sales Per Share 0.20
Book Value Per Share 0.46

Similar Companies

Related Articles

About Company

Australian radiopharmaceutical company, Cyclopharm Limited (ASX: CYC) is focused on innovative solutions in nuclear medicine, targeted towards lung health. Serving the global medicine community since 1986, the company’s proprietary medical device and pharmaceutical products are made available under TechnegasTM, which is considered as the industry gold-standard in diagnostic functional lung imaging technology. Cyclopharm distributes its products in 57 countries with more than 1,500 nuclear medicine departments using TechnegasTM.

Corporate Information


Unit 4, 1 The Crescent, KINGSGROVE, NSW, AUSTRALIA, 2208

Phone:(02) 9541 0411

Website:http://www.cyclopharm.com

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable
02/09/2016 $0.01 46% 30/06/2016 Interim Dividend 12/09/2016
11/04/2016 $0.01 100% 31/12/2015 Interim Dividend 19/04/2016
05/10/2015 $0.01 100% 30/06/2015 - 14/10/2015

Event Calendar

Event Type Event Date Event Year
Report (Interim) 2023-08-16 2023
Report (Annual) 2023-03-30 2023
Report (Prelim) 2023-02-22 2023